Cas No.: | 1929519-13-0 |
Chemical Name: | (S)-2-(4-Oxobenzo[d][1,2,3]triazin-3(4H)-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl)acetamide |
Synonyms: | (S)-2-(4-oxobenzo[d][1,2,3]triazin-3(4H)-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl)acetamide;2-(4-oxo-1,2,3-benzotriazin-3-yl)-N-[(1S)-1-[4-(trifluoromethoxy)phenyl]ethyl]acetamide;TAK041;GTPL11685;US9556130, test 2;BDBM263368;NBI1065846;compound 56 [PMID: 34260228] |
SMILES: | FC(OC1C([H])=C([H])C(=C([H])C=1[H])[C@]([H])(C([H])([H])[H])N([H])C(C([H])([H])N1C(C2=C([H])C([H])=C([H])C([H])=C2N=N1)=O)=O)(F)F |
Formula: | C18H15F3N4O3 |
M.Wt: | 392.3319 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | TAK-041 is a potent and selective GPR139 agonist with an EC50 of 22 nM. TAK-041 has the potential for the research of negative symptoms associated with schizophrenia[1]. |
Target: | GPR139, EC50:22 nM |
In Vivo: | TAK-041 (0.03-3 mg/kg; P.o.) improves social behavior in BALB/c mice[1]. Animal Model: BALB/c mice[1] Dosage: 0.03, 0.3, and 3 mg/kg Administration: P.o. Result: Dose-dependently improved the social behavior of BALB/c mice. |